The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

We need to diversify our HIV workforce with new roles that align with the health and well ... and nurse scientist with ...

A new study from Tulane University finds that historical race-based lending practices are still impacting health today, ...

Truvada, which is also marketed by Gilead (GILD), is approved for use as both a PrEP therapy and treatment for HIV infection ...

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

As the science stands, the vast majority of the roughly eight million people in South Africa living with HIV will have to get ...

What caused some of the STD trends to improve? Several experts say one contributor is the growing use of an antibiotic as a ...

Highly effective treatments for HIV have existed since the mid-1990s. But while these treatments keep people healthy, we do not yet have a safe and scalable way to completely rid the body of the virus ...

“These incredibly positive outcomes offer new hope at a time when 40 million ... we are witnessing for the first time a drug ...

Although sexually transmitted infections are still at an epidemic level in the US, scientists at the US Centers for Disease ...

The CDC did not break out most data for county or region, but for New York State in 2023 ... which tests people like those ...